Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Total Debt (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Total Debt for 4 consecutive years, with $43658.0 as the latest value for Q3 2025.

  • On a quarterly basis, Total Debt rose 101.38% to $43658.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $43658.0, a 101.38% increase, with the full-year FY2024 number at $20180.0, changed N/A from a year prior.
  • Total Debt was $43658.0 for Q3 2025 at bioAffinity Technologies, down from $45952.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $500000.0 in Q3 2022 to a low of $20180.0 in Q4 2024.
  • A 4-year average of $107994.4 and a median of $43658.0 in 2025 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: plummeted 86.32% in 2024, then skyrocketed 109.04% in 2025.
  • bioAffinity Technologies' Total Debt stood at $251746.0 in 2022, then tumbled by 83.18% to $42334.0 in 2023, then crashed by 52.33% to $20180.0 in 2024, then skyrocketed by 116.34% to $43658.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Total Debt are $43658.0 (Q3 2025), $45952.0 (Q2 2025), and $48156.0 (Q1 2025).